Evidence map›Paper›PMID 42835264›Full record

ArticleFrontiers in immunology2026

Case Report: Nicotinamide monotherapy for infantile bullous pemphigoid with long-term follow-up.

Peng Qu, Guizhi Zhou, Baoqi Yang

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Peng QuDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
Guizhi ZhouDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
Baoqi YangDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infantile bullous pemphigoid (IBP) is a rare autoimmune bullous skin disease that occurs in infants, for which standardized targeted therapeutic regimens remain unavailable. Herein, we report two infants with IBP treated with nicotinamide monotherapy. Complete clinical remission was observed within 3 weeks and 10 days after treatment initiation, respectively. Following clinical improvement, nicotinamide was gradually tapered and discontinued in approximately 2 months. No recurrence was observed during long-term follow-up. However, given the limited number of cases, these observations do not establish the therapeutic efficacy of nicotinamide but provide clinical experience with nicotinamide monotherapy in IBP.

Indexed as

NiacinamidePemphigoid, BullousFemaleFollow-Up StudiesHumansInfantMaleTreatment OutcomeNiacinamideautoimmune blistering diseaseinfantile bullous pemphigoidlong-term follow-upmonotherapynicotinamide

Identifiers

PMID42835264
PMCPMC13635102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.